Equities Analysts Set Expectations for SLDB FY2025 Earnings
Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.
GEN18h
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $16.00
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Zacks.com on MSN5d
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
It was a busy week for the biotech sector. While the fourth-quarter earnings season continues, other pipeline and regulatory ...
The Pharma Letter5d
Solid Biosciences surges on Duchenne therapy success
Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...
Solid Biosciences (SLDB) Gets a Buy from Barclays
In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target ...
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
JMP Securities Keeps Their Buy Rating on Solid Biosciences (SLDB)
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of ...